Effect of Liraglutide Combined With Short-term CSII on Long-term Glycemic Remission and β Cell Function

• Status: Unknown status
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate and evaluate the effects of liraglutide combined with short-term continuous subcutaneous insulin infusion(CSII) on long-term glycemic control and β-cell function in newly diagnosed type 2 diabetic patients.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sun Yat-sen University
• Treatments: Insulin; Liraglutide

Criteria

Inclusion Criteria:

• newly diagnosed type 2 diabetes

• fasting blood glucose (FBG) level ranging from 7.0-16.7mmol/L

• body mass index (BMI) ranging from 21-35kg/m2

• antihypercaemic and antihyperlipidemic medication-naive patients

Exclusion Criteria:

• having any severe acute or chronic diabetic complications

• renal dysfunction, blood creatinine>150umol/L

• blood aminotransferase level rising up(more than 2 times of the upper normal limit of ALT)

• any severe cardiac disease including congestive cardiac failure, unstable angina or myocardial infarct in 12 months

• chronic or acute pancreatic disease

• severe systemic diseases or malignant tumor

• female patients incline to be pregnant

• being treated with corticosteriod, immunosuppressing drugs or cytotoxic drugs

• poor compliance